Marti Dalmases
CEO
PhD, MD, MBA / Chief Executive Officer
PhD in Medicine - Univ. Autònoma de Barcelona (UAB); Master’s in business administration (UAB); Master’s in Scientific Communication at Univ. Pompeu Fabra (UPF); Master’s in Hyperbaric Medicine at Univ. Barcelona (UB).
Marti has had responsibilities in different environments of the health sector: hospital management; university lecturing; consultancy at national and international level; R&D+i project management; science divulgation as a founder of "Educación Médica" scientific review.
In recent years, Marti has been very active in the technology transfer field. He was Healthcare Director at KIM (Knowledge Innovation Market), and he has founded some start-up companies, or helped them to grow, participating as a business angel (BA investor and in some cases as a member of the Board). These include SOM Biotech (a drug repurposing company); TR Composites (carbon fiber components for aeronautics); Confirmsign (digital logistics provider); Nanosel (nanotech platform for cancer treatment); IDP Discovery Pharma (drug development to fight cancer) and Centauri Biotech (veterinary stem cell company). He is now the CEO of Ahead Therapeutics.
PhD in Medicine - Univ. Autònoma de Barcelona (UAB); Master’s in business administration (UAB); Master’s in Scientific Communication at Univ. Pompeu Fabra (UPF); Master’s in Hyperbaric Medicine at Univ. Barcelona (UB).
Marti has had responsibilities in different environments of the health sector: hospital management; university lecturing; consultancy at national and international level; R&D+i project management; science divulgation as a founder of "Educación Médica" scientific review.
In recent years, Marti has been very active in the technology transfer field. He was Healthcare Director at KIM (Knowledge Innovation Market), and he has founded some start-up companies, or helped them to grow, participating as a business angel (BA investor and in some cases as a member of the Board). These include SOM Biotech (a drug repurposing company); TR Composites (carbon fiber components for aeronautics); Confirmsign (digital logistics provider); Nanosel (nanotech platform for cancer treatment); IDP Discovery Pharma (drug development to fight cancer) and Centauri Biotech (veterinary stem cell company). He is now the CEO of Ahead Therapeutics.
Marta Vives Pi
Scientific Director
PhD, Scientific Director
Bachelor in Biological Science and PhD in Medicine and Surgery from the Universitat Autònoma de Barcelona (UAB). Associate professor of immunology at Can Ruti Hospital – UAB.
Director of the Immunology of Diabetes Research Group at Germans Trias Hospital. The research group is dedicated to the immunology of diabetes, and carries out both basic and translational research with the aim of developing preventive immunotherapeutic for type 1 diabetes and to identify the mechanisms of pathogenicity and regeneration in auto-immune diseases. The group’s research lines are: (i) Immunotherapies for the prevention and treatment of type 1 diabetes, (ii) Biomarkers for the regeneration of autoimmune diseases, (iii) Pathogenic mechanisms of autoimmunity, (iv) Paediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers.
Bachelor in Biological Science and PhD in Medicine and Surgery from the Universitat Autònoma de Barcelona (UAB). Associate professor of immunology at Can Ruti Hospital – UAB.
Director of the Immunology of Diabetes Research Group at Germans Trias Hospital. The research group is dedicated to the immunology of diabetes, and carries out both basic and translational research with the aim of developing preventive immunotherapeutic for type 1 diabetes and to identify the mechanisms of pathogenicity and regeneration in auto-immune diseases. The group’s research lines are: (i) Immunotherapies for the prevention and treatment of type 1 diabetes, (ii) Biomarkers for the regeneration of autoimmune diseases, (iii) Pathogenic mechanisms of autoimmunity, (iv) Paediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers.
Daniel Maspoch
Liposome Technology Director
PhD / Liposome Technology Director
Daniel's scientific career began with a degree in chemistry at the Universitat de Girona, followed by a PhD in materials science from the Universitat Autònoma de Barcelona and the Institut de Ciència de Materials de Barcelona. He then spent two years at Northwestern University (USA) as a postdoctoral fellow in the group led by Prof. Chad A. Mirkin. He has been an ICREA research professor and group leader at the ICN2 since September 2011. In 2014 Prof. Maspoch was awarded a prestigious ERC Consolidator Grant for the InanoMOF project to develop frontier methodologies for the synthesis of nanocomposites made from MOFs. In 2015 he received the Marcial Moreno Mañas Lectureship award. He has authored over 115 papers and five book chapters. He moved back to the then ICN thanks to a Ramón y Cajal contract, where he founded the ICN2 Supramolecular Nanochemistry and Materials Group. He has been an ICREA Research Professor and group leader at the ICN2 since September 2011. In 2014 he was awarded an ERC Consolidator Grant.
Prof. Maspoch has authored 97 scientific publications and five book chapters. He has also filed eight patents and established 14 contracts with private companies, including two patent licence agreements and three successful transfers of in-house technology for immediate application in consumer products.
Daniel's scientific career began with a degree in chemistry at the Universitat de Girona, followed by a PhD in materials science from the Universitat Autònoma de Barcelona and the Institut de Ciència de Materials de Barcelona. He then spent two years at Northwestern University (USA) as a postdoctoral fellow in the group led by Prof. Chad A. Mirkin. He has been an ICREA research professor and group leader at the ICN2 since September 2011. In 2014 Prof. Maspoch was awarded a prestigious ERC Consolidator Grant for the InanoMOF project to develop frontier methodologies for the synthesis of nanocomposites made from MOFs. In 2015 he received the Marcial Moreno Mañas Lectureship award. He has authored over 115 papers and five book chapters. He moved back to the then ICN thanks to a Ramón y Cajal contract, where he founded the ICN2 Supramolecular Nanochemistry and Materials Group. He has been an ICREA Research Professor and group leader at the ICN2 since September 2011. In 2014 he was awarded an ERC Consolidator Grant.
Prof. Maspoch has authored 97 scientific publications and five book chapters. He has also filed eight patents and established 14 contracts with private companies, including two patent licence agreements and three successful transfers of in-house technology for immediate application in consumer products.
Antonia Maria Cano Sarabia
Liposome Synthesis Consultant
PhD / Liposome Synthesis Consultant
Dr. Antonia María Cano Sarabia received her B.Sc. in Chemical Engineering from the University of Murcia in 2002. From 2002 to 2003, she was a fellow in the research group of Industrial Hygiene and Safety led by Prof. Agustín Miñana/Dr. José Ruiz Gimeno at the University of Murcia. She worked on the development of emergency plans in industrial plants.
Awarded a 4-year FPU fellowship in 2004, she began her doctoral studies at the Materials Science Institute of Barcelona (ICMAB), under the guidance of Dr. Nora Ventosa/Prof. Jaume Veciana. Her PhD thesis was focused on developing novel supercritical fluid technologies for preparing functional organic nanomaterials for biomedical applications. In 2008 she was a visiting researcher at the Institute Galien Paris-Sud, in the group led by Prof. Patrick Couvreur (UMR CNRS 8612). Dr. Cano received her PhD (Cum Laude) in Material Sciences from the Universitat Autònoma de Barcelona in 2009. That same year, she was awarded a Marie-Curie Postdoctoral EIC-SMEInst-2018-2020 Fellowship. As a postdoctoral researcher, she worked on developing plastic nanochromic displays at the NTERA company (Dublin, Ireland) under confidentiality clauses. Since mid-2010, Dr. Cano has coordinated the Division of Nano- and Microencapsulation of the Supramolecular NanoChemistry & Materials (NANOUP) research group.
Dr. Antonia María Cano Sarabia received her B.Sc. in Chemical Engineering from the University of Murcia in 2002. From 2002 to 2003, she was a fellow in the research group of Industrial Hygiene and Safety led by Prof. Agustín Miñana/Dr. José Ruiz Gimeno at the University of Murcia. She worked on the development of emergency plans in industrial plants.
Awarded a 4-year FPU fellowship in 2004, she began her doctoral studies at the Materials Science Institute of Barcelona (ICMAB), under the guidance of Dr. Nora Ventosa/Prof. Jaume Veciana. Her PhD thesis was focused on developing novel supercritical fluid technologies for preparing functional organic nanomaterials for biomedical applications. In 2008 she was a visiting researcher at the Institute Galien Paris-Sud, in the group led by Prof. Patrick Couvreur (UMR CNRS 8612). Dr. Cano received her PhD (Cum Laude) in Material Sciences from the Universitat Autònoma de Barcelona in 2009. That same year, she was awarded a Marie-Curie Postdoctoral EIC-SMEInst-2018-2020 Fellowship. As a postdoctoral researcher, she worked on developing plastic nanochromic displays at the NTERA company (Dublin, Ireland) under confidentiality clauses. Since mid-2010, Dr. Cano has coordinated the Division of Nano- and Microencapsulation of the Supramolecular NanoChemistry & Materials (NANOUP) research group.
Silvia Rodriguez Vidal
Technical Director
Chemical Engineer / Technical Director
Chemical Engineer & Bachelor in organic Chemistry from the Institut Quimic de Sarria (IQS). She is currently the technical director of Ahead Therapeutics. She has broad experience in the synthesis and scale-up of Pharmaceutically Active Ingredients as well as Business Development in the Pharmaceutical Industry.
She previously worked in the R&D department at Haarmann & Reimer (Spain). In 2000, she was granted the European Leonardo da Vinci fellowship that funded practical projects in the field of vocational education and training and spent a year working for Specialist Bioanalytical Services Limited (Egham, Surrey, UK) improving the analysis data tool for GC/MS & LC/MS/MS daughter ion testing. In 2001, she joined LEBSA, an API manufacturer in Barcelona (Spain) where she was manager of the R&D Department. Before joining Ahead Therapeutics, she also worked for Eurofins BioPharma Product Testing, the world leading supplier of laboratory testing services, as Technical adviser and Project manager.
Chemical Engineer & Bachelor in organic Chemistry from the Institut Quimic de Sarria (IQS). She is currently the technical director of Ahead Therapeutics. She has broad experience in the synthesis and scale-up of Pharmaceutically Active Ingredients as well as Business Development in the Pharmaceutical Industry.
She previously worked in the R&D department at Haarmann & Reimer (Spain). In 2000, she was granted the European Leonardo da Vinci fellowship that funded practical projects in the field of vocational education and training and spent a year working for Specialist Bioanalytical Services Limited (Egham, Surrey, UK) improving the analysis data tool for GC/MS & LC/MS/MS daughter ion testing. In 2001, she joined LEBSA, an API manufacturer in Barcelona (Spain) where she was manager of the R&D Department. Before joining Ahead Therapeutics, she also worked for Eurofins BioPharma Product Testing, the world leading supplier of laboratory testing services, as Technical adviser and Project manager.
Raul Insa
Business Development Advisor
MD, PhD, MBA /: Business Development Advisor
Bachelor’s in Medicine and Surgery. Doctorate in Clinical Neurology and Extraordinary PhD Award (University of Alicante). He completed his scientific background with several business postgraduate programmes (MBA ESADE, PDD IESE, Leadership and Strategy in Pharmaceuticals and Biotech, HARVARD Business School, and Leading Science-Based Enterprises, HARVARD Business School).
He has worked in different multinational companies such as Parke-Davis S.A (Warner- Lambert Group), UCB Pharma, J. URIACH, ISDIN S.A. He has held different roles in these organizations, including Clinical Product Development, Medical & Regulatory Director and Project and Development Director.
In 2009, he founded a Bio-pharmaceutical company called SOM Biotech S.L. that is specialized in drug repositioning. Located in Barcelona Science Park, he is currently its CEO.
Bachelor’s in Medicine and Surgery. Doctorate in Clinical Neurology and Extraordinary PhD Award (University of Alicante). He completed his scientific background with several business postgraduate programmes (MBA ESADE, PDD IESE, Leadership and Strategy in Pharmaceuticals and Biotech, HARVARD Business School, and Leading Science-Based Enterprises, HARVARD Business School).
He has worked in different multinational companies such as Parke-Davis S.A (Warner- Lambert Group), UCB Pharma, J. URIACH, ISDIN S.A. He has held different roles in these organizations, including Clinical Product Development, Medical & Regulatory Director and Project and Development Director.
In 2009, he founded a Bio-pharmaceutical company called SOM Biotech S.L. that is specialized in drug repositioning. Located in Barcelona Science Park, he is currently its CEO.
Bernabé Zea
IP Strategy Advisor
MSc, / IP strategy Advisor.
MSc in Chemistry / Spanish Patent and Trademark Attorney / European Trademark and Design Attorney.
Bernabé has been working in the areas of patent, technology transfer and information retrieval since his graduation in 1988. Throughout his whole professional life he has been training people from his position in the Centre de Patents at the University of Barcelona. He first lectured on information retrieval, mainly scientific and patent searching, and later on the patent system and more recently on technology transfer.
Although he has been part of the University of Barcelona for his whole professional career, he has always has made this position compatible with other roles, first working for multinational companies like Chemical Abstracts Service and Questel-Orbit, and later with very well-prepared colleagues, founding their own companies: ZBM Patents and Trademarks, and ZBM Business Connect. Ahead Therapeutics is the last and probably the most important project he has been involved in.
In fact, his professional career has always been about striking the right balance between starting new projects and carrying out real technical work and teaching people about those experiences.
MSc in Chemistry / Spanish Patent and Trademark Attorney / European Trademark and Design Attorney.
Bernabé has been working in the areas of patent, technology transfer and information retrieval since his graduation in 1988. Throughout his whole professional life he has been training people from his position in the Centre de Patents at the University of Barcelona. He first lectured on information retrieval, mainly scientific and patent searching, and later on the patent system and more recently on technology transfer.
Although he has been part of the University of Barcelona for his whole professional career, he has always has made this position compatible with other roles, first working for multinational companies like Chemical Abstracts Service and Questel-Orbit, and later with very well-prepared colleagues, founding their own companies: ZBM Patents and Trademarks, and ZBM Business Connect. Ahead Therapeutics is the last and probably the most important project he has been involved in.
In fact, his professional career has always been about striking the right balance between starting new projects and carrying out real technical work and teaching people about those experiences.
Bruna Barneda Zahonero
PhD, MBA/ Pre-Clinical & Clinical Development Director
PhD, MBA/ Pre-Clinical & Clinical Development Director
Bruna joined Ahead’s Therapeutics team on December 2018. She is a professional with more than 2 years in the intellectual property sector, a master's degree in business administration (MBA) and more than 12 years of experience in R&D projects in the field of Biomedicine.
She holds an Msc and a Ph.D. in Molecular Biology and Biochemistry (UAB), and an Msc in business administration (UPF-La Salle BES).
During her scientific career, Bruna carried out biomedical research at different competitive laboratories placed in the Universitat Autonoma of Barcelona (UAB), the Bellvitge Biomedical Research Institute (IDIBELL) and Vall d'Hebron Research Institute (VHIR). There, she was engaged in the coordination and management of R&D projects focused on neuroscience, cancer and epigenetics fields, and actively involved in teaching tasks at the University.
Before joining Ahead Therapeutics, she worked in ZBM Patents & Trademarks as a Business development manager and Patent advisor. Were she was involved in the dynamization of R&D projects from the initial idea definition and the Intellectual property strategy, to product planning and market uptake
Bruna joined Ahead’s Therapeutics team on December 2018. She is a professional with more than 2 years in the intellectual property sector, a master's degree in business administration (MBA) and more than 12 years of experience in R&D projects in the field of Biomedicine.
She holds an Msc and a Ph.D. in Molecular Biology and Biochemistry (UAB), and an Msc in business administration (UPF-La Salle BES).
During her scientific career, Bruna carried out biomedical research at different competitive laboratories placed in the Universitat Autonoma of Barcelona (UAB), the Bellvitge Biomedical Research Institute (IDIBELL) and Vall d'Hebron Research Institute (VHIR). There, she was engaged in the coordination and management of R&D projects focused on neuroscience, cancer and epigenetics fields, and actively involved in teaching tasks at the University.
Before joining Ahead Therapeutics, she worked in ZBM Patents & Trademarks as a Business development manager and Patent advisor. Were she was involved in the dynamization of R&D projects from the initial idea definition and the Intellectual property strategy, to product planning and market uptake
Miriam Salvadó
PhD / CMC Scientist & Laboratory Manager
PhD / CMC Scientist & Laboratory Manager
Dr. Míriam Salvadó joined Ahead Therapeutics on February, 2019, as a CMC Scientist & Laboratory Manager.
She received her BSc with honours in Biochemistry, MSc in Synthesis and Catalysis and her PhD (Cum Laude) in Organic Chemistry from the Universitat Rovira i Virgili. She is also pursuing a post-graduate course in Quality Systems in the pharmaceutical industry and research, from the Universitat de Barcelona.
In 2011, she obtained a pre-graduate fellowship in the Biochemistry Department (URV) and in the group led by Prof. Ellen Billet in Nottingham Trent University (UK). Her work was focused on glycolipid and glycopolymers synthesis and the study of glycolipid-protein interactions. She had the opportunity to join Prof. Jesús Jiménez-Barbero’s group in CSIC (Madrid) in order to study these interactions using NMR. In 2015 she received a fellowship as a visiting researcher in the University of Cambridge (UK), where she worked in protein modification and protein-based nanocapsules.
Dr. Míriam Salvadó joined Ahead Therapeutics on February, 2019, as a CMC Scientist & Laboratory Manager.
She received her BSc with honours in Biochemistry, MSc in Synthesis and Catalysis and her PhD (Cum Laude) in Organic Chemistry from the Universitat Rovira i Virgili. She is also pursuing a post-graduate course in Quality Systems in the pharmaceutical industry and research, from the Universitat de Barcelona.
In 2011, she obtained a pre-graduate fellowship in the Biochemistry Department (URV) and in the group led by Prof. Ellen Billet in Nottingham Trent University (UK). Her work was focused on glycolipid and glycopolymers synthesis and the study of glycolipid-protein interactions. She had the opportunity to join Prof. Jesús Jiménez-Barbero’s group in CSIC (Madrid) in order to study these interactions using NMR. In 2015 she received a fellowship as a visiting researcher in the University of Cambridge (UK), where she worked in protein modification and protein-based nanocapsules.